摘要:
Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.
摘要:
Alkynyl pyrrolo [2,3-d] pyrimidines of Formula I are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.
摘要:
Novel purine compounds of Formula I. and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O)2; and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl, and heterocyclic, all optionally substituted, are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.
摘要:
Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.
摘要:
Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.
摘要:
The present invention provides compounds represented by Formula I. R0 is selected from hydrogen, halogen, lower alkyl, —SR8, —OR8, —CN, and —NHR8, R1 is halogen, or lower alkyl; R2 is —NHR8; R3 is selected from the group consisting of hydrogen, halogen, —SR8, —OR8, —CN, —C(O)R9, —C(O)OH, —NO2, —NR8R10, lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, and R5 is aryl, heteroaryl, alicyclic, or heterocyclic:
摘要翻译:本发明提供由式I表示的化合物。R 0选自氢,卤素,低级烷基,-SR 8,-OR 8, ,-CN和-NHR 8,R 1是卤素或低级烷基; R 2是-NHR 8; R 3选自氢,卤素,-SR 8,-OR 8,-CN,-C(O) R 9,-C(O)OH,-NO 2,-NR 8 R 10,低级烷基 ,低级烯基,低级炔基,低级全卤代烷基,芳基,杂芳基,脂环族和杂环基,全部被取代,R 5是芳基,杂芳基,脂环族或杂环基:
摘要:
An optical switch system for dropping a ROADM node is presented. The switch system includes an N×M structure having two layers. A first layer includes optical splitters, each splitter receiving a multiplexed input signal and outputting a first multiplexed output signal. A second layer includes switches receiving the first multiplexed output signals from the optical splitters and generating a second multiplexed output signal. The second multiplexed output signal is typically one of the first multiplexed output signals. An optional third layer, which includes optical filters, receives the second multiplexed output signal from the switches and produces a non-multiplexed, single-wavelength output signal.
摘要:
An optical switch system for dropping a ROADM node is presented. The switch system includes an N×M structure having two layers. A first layer includes optical splitters, each splitter receiving a multiplexed input signal and outputting a first multiplexed output signal. A second layer includes switches receiving the first multiplexed output signals from the optical splitters and generating a second multiplexed output signal. The second multiplexed output signal is typically one of the first multiplexed output signals. An optional third layer, which includes optical filters, receives the second multiplexed output signal from the switches and produces a non-multiplexed, single-wavelength output signal.
摘要:
Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.
摘要:
In an example embodiment, a bundle loader is run in response to a communication from an application. The communication may indicate that the plurality of bundles of components in the application is to be executed. The plurality of bundles may include at least one bundle having a component that depends on a dependency component in another of the plurality of bundles. A configuration file indicating a set of the plurality of bundles to load in the bundle loader is received. The bundle loader is operated to load a bundle manifest for each bundle in the set of the plurality of bundles to load. Then, for each of the bundles in the set of plurality of bundles to load, the bundle is activated if no unactivated dependency component exists for any component in the bundle.